Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Leukemia, Myeloid, Acute 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Cholangiocarcinoma 1Carcinoma 1

Interventions

Paclitaxel 17Carboplatin 16Magnetic Resonance Spectroscopy 11Taxes 10Specimen Handling 10Bevacizumab 10olaparib 9Gemcitabine 9pembrolizumab 8Immunoglobulin G 7Disulfides 7Biopsy 7liposomal doxorubicin 6Doxorubicin 5cediranib 4Nivolumab 4Cyclophosphamide 4Cisplatin 4oregovomab 3niraparib 3adavosertib 3X-Rays 3Topotecan 3tremelimumab 2rucaparib 2mirvetuximab soravtansine 2berzosertib 2aldesleukin 2Surveys and Questionnaires 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Fallopian Tube Neoplasms × peposertib × Clear all
NCT04092270 2026-05-13

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
54 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡